132 related articles for article (PubMed ID: 22574550)
41. Baseline and decline of serum ADAM28 during chemotherapy of advanced non-small cell lung cancer: a probable predictive and prognostic factor.
Lv YL; Yuan DM; Wang QB; Zhan P; Luo L; Lv TF; Liu HB; Li YF; Wen J; Song Y
Med Oncol; 2012 Dec; 29(4):2633-9. PubMed ID: 22354764
[TBL] [Abstract][Full Text] [Related]
42. [Assessment of concentrations of A, C and E vitamins in the plasma of patients with NSCLC undergoing first-line chemotherapy].
Tokarski S; Rutkowski M; Mejer A; Godala M; Kowalski J
Pol Merkur Lekarski; 2013 Jul; 35(205):18-21. PubMed ID: 23984600
[TBL] [Abstract][Full Text] [Related]
43. Reduction of Serum Cytokeratin-3A9 is Associated with Chemotherapeutic Response in Patients with Non-Small Cell Lung Cancer.
Shi GL; Wu ED; Sun Y; Yin YJ; Song CX
Clin Lab; 2015; 61(5-6):497-504. PubMed ID: 26118182
[TBL] [Abstract][Full Text] [Related]
44. [Effect of traditional Chinese medicine treatment as maintenance therapy on regulating the serum concentration of sCTLA-4 in patients with advanced non-small-cell lung cancer and its relationship with prognosis].
Jiang Y; Wu LB; Shen LP; Zhang P; Jiang WJ; Tian JH; Liu LS
Zhonghua Zhong Liu Za Zhi; 2016 Oct; 38(10):757-762. PubMed ID: 27784460
[No Abstract] [Full Text] [Related]
45. Prognostic and predictive value of plasma D-dimer in advanced non-small cell lung cancer patients undergoing first-line chemotherapy.
Ge LP; Li J; Bao QL; Chen P; Jiang Q; Zhu LR
Clin Transl Oncol; 2015 Jan; 17(1):57-64. PubMed ID: 24997087
[TBL] [Abstract][Full Text] [Related]
46. Identification of serum proteins and multivariate models for diagnosis and therapeutic monitoring of lung cancer.
Ma R; Xu H; Wu J; Sharma A; Bai S; Dun B; Jing C; Cao H; Wang Z; She JX; Feng J
Oncotarget; 2017 Mar; 8(12):18901-18913. PubMed ID: 28121629
[TBL] [Abstract][Full Text] [Related]
47. C-reactive protein is a significant predictor of improved survival in patients with advanced non-small cell lung cancer.
Xiao X; Wang S; Long G
Medicine (Baltimore); 2019 Jun; 98(26):e16238. PubMed ID: 31261584
[TBL] [Abstract][Full Text] [Related]
48. In vitro exposure of NK-92 cells to serum from patients with non-small cell lung cancer impairs their cytotoxicity.
Tsartsalis D; Grapsa D; Skopeliti M; Dragioti E; Charpidou A; Politi E; Tsitsilonis O; Syrigos K
Anticancer Res; 2015 Mar; 35(3):1543-8. PubMed ID: 25750309
[TBL] [Abstract][Full Text] [Related]
49. Anemia in patients with advanced or metastatic non-small cell lung cancer.
Abuzallouf S; Wright J; El Hattab O
Gulf J Oncolog; 2007 Jan; 1(1):17-21. PubMed ID: 20084709
[TBL] [Abstract][Full Text] [Related]
50. Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value.
Srdic D; Plestina S; Sverko-Peternac A; Nikolac N; Simundic AM; Samarzija M
Support Care Cancer; 2016 Nov; 24(11):4495-502. PubMed ID: 27236439
[TBL] [Abstract][Full Text] [Related]
51. Immunomodulatory effects of chemotherapy on blood lymphocytes and survival of patients with advanced non-small cell lung cancer.
Aldarouish M; Su X; Qiao J; Gao C; Chen Y; Dai A; Zhang T; Shu Y; Wang C
Int J Immunopathol Pharmacol; 2019; 33():2058738419839592. PubMed ID: 30968711
[TBL] [Abstract][Full Text] [Related]
52. Predictive and prognostic value of serum periostin in advanced non-small cell lung cancer patients receiving chemotherapy.
Zhang Y; Yuan D; Yao Y; Sun W; Shi Y; Su X
Tumour Biol; 2017 May; 39(5):1010428317698367. PubMed ID: 28459197
[TBL] [Abstract][Full Text] [Related]
53. The effect of Radachlorin® PDT in advanced NSCLC: a pilot study.
Ji W; Yoo JW; Bae EK; Lee JH; Choi CM
Photodiagnosis Photodyn Ther; 2013 May; 10(2):120-6. PubMed ID: 23769277
[TBL] [Abstract][Full Text] [Related]
54. Circulating Thrombospondin-2 and FGF-2 in Patients with Advanced Non-small Cell Lung Cancer: Correlation with Survival.
Naumnik W; Ossolińska M; Płońska I; Chyczewska E; Nikliński J
Adv Exp Med Biol; 2015; 833():9-14. PubMed ID: 25298262
[TBL] [Abstract][Full Text] [Related]
55. Serum cathepsin K and cystatin C concentration in patients with advanced non-small-cell lung cancer during chemotherapy.
Naumnik W; Niklińska W; Ossolińska M; Chyczewska E
Folia Histochem Cytobiol; 2009; 47(2):207-13. PubMed ID: 19995705
[TBL] [Abstract][Full Text] [Related]
56. Comparison of C-reactive protein levels in patients with lung cancer and chronic obstructive pulmonary disease.
Vagulienė N; Žemaitis M; Miliauskas S; Urbonienė D; Šitkauskienė B; Sakalauskas R
Medicina (Kaunas); 2011; 47(8):421-7. PubMed ID: 22123552
[TBL] [Abstract][Full Text] [Related]
57. [Correlation of initial DNA damage detected by alkaline comet assay and clinical endpoints in lung cancer patients].
Lv J; Wang L; Yang W; Zhang X; Wang M; Yan J
Zhongguo Fei Ai Za Zhi; 2006 Apr; 9(2):187-91. PubMed ID: 21144308
[TBL] [Abstract][Full Text] [Related]
58. Blood gas analysis, blood saturation and chosen parameters of spirometric examination in NSCLC patients undergoing chemotherapy and pulmonary rehabilitation.
Tokarski S; Tokarska K; Schwarz E; Obrebska A; Mejer A; Kowalski J
Pol Merkur Lekarski; 2014 Apr; 36(214):249-53. PubMed ID: 24868897
[TBL] [Abstract][Full Text] [Related]
59. Cancer-related inflammation as predicting tool for treatment outcome in locally advanced and metastatic non-small cell lung cancer.
Badovinac S; Korsic M; Mursic D; Samarzija M; Cucevic B; Roglic M; Jakopovic M
J Thorac Dis; 2016 Jul; 8(7):1497-503. PubMed ID: 27499936
[TBL] [Abstract][Full Text] [Related]
60. actate Dehydrogenase (LDH) as a Tumor Marker for Non-small Cell Lung Cancer.
Yuh YJ; Kim SR
Cancer Res Treat; 2002 Oct; 34(5):339-44. PubMed ID: 26680885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
